About Us – Prognica Labs

About Us

We are an AI-driven biotech company redefining how drug assets are discovered, evaluated, and advanced. We combine autonomous intelligence with deep human expertise to identify overlooked or discontinued molecules and accelerate them through early clinical stages. We are building a lean, next-generation alternative to traditional pharma R&D – powered by a fully integrated stack of AI agents that automate scientific diligence, in-silico validation, clinical feasibility modeling, and deal structuring. We are transforming drug development by dramatically reducing time, cost, and risk, turning hidden opportunities into breakthrough therapies for patients.

Our Mission

End‑to‑end stack of AI agents and human expert review to discover, evaluate, de‑risk, develop (to early clinical stages) and commercialize overlooked or abandoned drug assets.

Our Vision

To become a global leader in next-generation biotech innovation, where every promising idea, molecule, or technology has a clear path from lab to life. We envision a world where healthcare is proactive and personalized, and life-changing therapies reach people when they need them the most.

We are AI-driven innovators fast and precise a lean R&D engine built for rapid breakthroughs

Scientifically Rooted, Commercially Driven

Our team is rooted in academic excellence – PhDs, leading researchers, and experienced biotech operators – but we operate like a startup: fast, iterative, and outcome-focused.

Platform-First
Strategy

We’re not just developing one drug or diagnostic. We’re building platforms – technologies that can be reused, adapted, and scaled across multiple disease areas.

Data + Biology
Synergy

By combining advanced analytics, machine learning, and experimental biology, we uncover insights faster and more precisely, helping us de-risk development and accelerate timelines.

Partnership
Mindset

We don’t go it alone. We partner with academic labs, pharma companies, and other startups to co-create, co-develop, and co-scale.

Our Core Team

Khalid Shaikh

Founder, CEO

A serial entrepreneur, researcher, author, and business strategist. Member of HBR Advisory Council. Received numerous awards for his contribution in healthcare and public health. He has published and lectured extensively on healthcare performance improvement, digitalization, and innovation

Dr. Mesk Alhammadi

Medical Director

A physician and a graduate of Yale University’s Master of Public Health program, with a concentration in Social and Behavioral Sciences. She is also a research assistant in Yale’s Department of Pulmonary, Critical Care & Sleep Medicine. She also led awareness campaigns on Alzheimer’s disease and cardiovascular health and participated in several community health initiatives.

Dr. Rohit Thanki

Director – Technology & Research

Stanford & Elsevier’s Top 2% Global Scientists. Senior AI/ML Scientist with over 15+ years of research experience and 8+ years in regulated MedTech development across Germany, the UAE, and India. Expertise lies at the intersection of AI, medical imaging, regulatory compliance, and healthcare innovation. Published 20+ books, 120+ research articles

Dr. Hashem Mirmazloumi

Genetics & Life Science

Medical geneticist and MBA, a healthcare business advisor , with speciality in Cytogenetics, FISH, and genomics. Over a decade of operation management, commercial development, and business strategy in the Middle East and Asia.

Sabitha K

AI / ML Scientist

M.E. in Biomedical Engg, B.E. in Comp. Sci. 8+ years of R & D experience in AI/ML in healthcare

Our Advisors

Dr. Sten Vermund, MD, PhD

President, Anna M.R. Lauder Professor of Public Health Former Dean (2017-2022) of the Yale School of Public Health Infectious disease epidemiologist focused on LMIC

Dr. Douglas Anthony, MD, PhD

Professor of Pathology and Laboratory Medicine Professor of Neurology at Alpert Medical School of Brown University Associate Director for Translational Research at Lifespan Cancer Institute

Dr. Faheem Hyder, PhD

Neuropharmacology expert with 9+ years in drug discovery, pioneering therapies for neurological disorders and cancers, integrating AI, leading teams, and translating complex science into impactful healthcare solutions.

Dr. Ibrahim Bani, MBBS, PhD

Adjunct Associate Professor at Yale University Associate Professor at Ajman University, UAE Worked with international Agencies WHO, UN, MI, UNC

Dr. Keerti Pradhan

Experienced in health sector program development, strategy, planning and management, working for Government, Private, Charity and Corporate groups in the Asian and African countries.

Clients & Partners